Gavin Jelic-Masterton Appointed as CEO of FINOX Biotech
7/1/2013 7:15:09 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
FINOX Biotech (Finox AG) announced today that it has appointed Gavin Jelic-Masterton as CEO.
Mr Jelic-Masterton, previously the company’s Senior Vice-President of Marketing & Commercial Operations,
joined FINOX Biotech in February 2013 and has more than 15 years experience in pharmaceutical and
biotech marketing and sales.
FINOX Biotech submitted their application for Marketing Authorisation Application (MAA) for its biosimilar
recombinant Follicle Stimulating Hormone (r-FSH) BEMFOLA® to the European Medicines Agency (EMA) on
October 30th 2012 and are therefore entering into a new phase in the company’s history – a phase that
requires strong leadership with experience in the marketing and commercialisation of fertility hormones.
Gavin Jelic-Masterton has been responsible for local and global marketing for fertility hormones for two of the
world’s leading manufacturers of gonadatrophins since 2000 – first at Merck Serono and latterly at Ferring
Pharmaceuticals, where he held positions of increasing seniority.
Dr. h.c. Willy Michel, President of the Board of FINOX Biotech commented, ‘Mr Jelic-Masterton has a proven
track record in marketing and selling fertility hormones and he is the right person to lead the company from
the development phase into the commercialisation phase and to create optimum value for the shareholders
and investors in the company. We would also like to take this opportunity to thank the outgoing CEO, Mr
Anjan Selz who decided to leave the company to undertake new challenges in Australia.’
BEMFOLA® (development code “AFOLIA”) is a new “biosimilar” medicine that was produced using
recombinant DNA technology. Both BEMFOLA® and the reference product Gonal-f® are formulations of the
naturally occurring hormone FSH, which plays a key role in human reproduction. BEMFOLA® is the result of
a targeted drug development process aimed to replicate as closely as possible the reference product.
BEMFOLA® has a number of key beneficial characteristics. i.e. equivalent clinical efficacy and safety vs.
Gonal-f®, but using an innovative and award winning injector device. The BEMFOLA® injector pen is a
single-use, one-a-day disposable device, which is smaller, more discreet and allows the patient to inject
using only the minimal numbers of steps – and has therefore been designed to increase patient confidence
by limiting the number of potential errors.
About BEMFOLA® in other clinical development programs
FINOX Biotech has agreed with the US-FDA via a Special Protocol Assessment to conduct a pivotal phase
III study (FIN3002) for registration of BEMFOLA® (AFOLIA) in the USA. A US IND was filed and the FIN3002
study is in progress.
About FINOX Biotech
FINOX Biotech (FINOX AG) is a biopharmaceutical company with its corporate headquarters in Burgdorf,
Switzerland. Finox’ first product will be BEMFOLA®, a biosimilar r-FSH of Gonal-f®. FINOX Biotech was
founded in 2007 with a vision to become a leading company in the field of fertility therapies, by combining
high quality Swiss medicines with innovative and award winning delivery devices.
For further information please visit www.finox.ch or contact our CEO, Gavin Jelic-Masterton
(email@example.com / +41 79 444 4110)
FINOX Biotech / Technikumstrasse 2 / 3401 Burgdorf / Switzerland
Help employers find you! Check out all the jobs and post your resume.